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High speed imaging of fluid dosing to mouse airways 
 ABSTRACT 
Background 
The manner in which fluid instillations into mouse nose and lung distribute through the airways is 
poorly understood. Many agents are delivered in this way for testing as therapeutics, or as 
challenges designed to establish infections or create systemic drug delivery effects. These agents 
are delivered into mouse airways with little knowledge of the manner in which doses move through 
the airways, how long they reside in each region, and where the instilled materials eventually reach. 
Methods 
Synchrotron phase contrast x-ray imaging (PCXI) was used to elucidate the primary controlling 
characteristics of mouse airway fluid dosing. High speed image acquisition was utilised to track the 
movement of a range of bolus doses of an iodine-based contrast fluid through the nose (n=15) and 
lungs (n=10) of live anaesthetized mice. For the lung studies the mice were ventilated and 
paralysed to control animal movement. Post-experiment image processing was employed to 
visualize the fluid movement. 
Results 
The maximum dose that could be retained in only the anterior nose was ~7.5 µl (20 g mouse), and 
a range of dynamic dose behaviours were documented after delivery. In the lung the use of 
mechanical ventilation in combination with a paralytic agent prevented confounding artefactual 
movement, improving visualization of fluid progression through the airways. In the lung, optimized 
image analysis utilizing the high image capture rate revealed the presence of respiratory pauses 
that could not be visualized at slower acquisition rates. The variability in the outcome of identical 
dose deliveries in different animals indicates that uniform lung distribution cannot be expected to 
occur with tracheal fluid delivery. 
 Conclusions 
With adequate imaging rate and fluid dose parameters this study shows the utility of synchrotron 
PCXI for determining the post-delivery behaviour and fate of fluid doses such as those used in in 
vivo gene transfer or pharmaceutical studies. 
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 INTRODUCTION 
The murine respiratory system is commonly used for disease modelling as well as for testing and 
developing potential treatments for respiratory diseases such as cystic fibrosis (CF), a genetic 
condition that primarily affects the conducting airways of the lung. Our group routinely uses the 
nose and lungs of normal and CFTR null mice as in vivo test sites for developing a gene therapy 
treatment for CF airway disease 1, 2. CFTR null mice do not exhibit CF pathophysiology in the lungs 
3, so in these mice the target of our gene therapy treatment is the ciliated respiratory epithelium in 
the proximal nose. Our HIV-1 based lentiviral (LV) gene vector used to package the therapeutic 
(CFTR) gene and / or a reporter gene is delivered to the nose or trachea by in vivo bolus instillation, 
primarily because this method produces better transduction than currently available aerosolisation 
methods. 
The success of airway gene transfer protocols depends on reliable fluid dosing but despite using 
standardized delivery techniques we, along with other groups, report large variability in both 
electrophysiological gene transfer measurements and reporter gene histological assessments 2-4. 
Heterogeneous dose distributions that may occur in the physically complex nose and trachea could 
be one cause of this variability. 
All standard imaging modalities (i.e. radiographs and ultrasound) poorly discriminate soft tissues 
from air-containing structures and cannot be used to visualize fluid dosing dynamics in the mouse 
nose and lung due to their limited spatial and temporal resolution. Similarly, while capable of 
providing 3-dimensional (3D) information via tomographic approaches, small-animal µ-CT and µ-
MRI cannot be used to track high speed dynamic events such as fluid dosing at high spatial 
resolutions. The ultimate location of trans-nasally delivered solutions has been determined in 3D 
using PET 5, but the acquisition speed and spatial resolution of nuclear medicine, SPECT and PET 
are too low to permit imaging of the dynamics of the fluid delivery. 
Synchrotron phase contrast X-ray imaging (PCXI) 6, 7 can be used to monitor the fate of a fluid 
dose bolus with high temporal and spatial resolution in the period immediately after delivery. A 
 synchrotron is a large machine that accelerates electrons to close to the speed of light. As the 
electrons are deflected through a magnetic field (e.g. at a bending magnet) they create extremely 
bright and coherent synchrotron light that is directed into experimental hutches. PCXI provides 
enhanced image contrast by utilizing X-ray refraction in addition to conventional X-ray absorption 
and is capable of producing soft tissue contrast even where the absorption differences are small, 
particularly in the lungs (see figure 1 on Page 5033 in Lewis et. al. 8 for a comparison between 
PCXI and standard absorption contrast). Propagation-based PCXI requires a spatially coherent X-
ray source, a property that is readily achievable using a synchrotron. The boundaries between 
tissue and air are enhanced by the phase changes in the incident X-ray wave induced by their 
differences in X-ray refractive index 6, 7. We have described the advantages of PCXI for airway 
surface imaging in small animals 9, 10; for monitoring the post-deposition behaviour of particulates 
on live mouse nasal and tracheal airways 11, 12; and for non-invasively tracking how a fluid bolus – 
typical of that used in airway gene therapy dosing – moves through the airways of live and intact 
small animals 13. 
Our previous fluid dosing study 13 showed the immediate fate of fluids instilled into the nose and 
trachea of live anaesthetized mice, demonstrating that the overall distribution of the dose, the 
effectiveness of the delivery method and the persistence of the delivered dose can now be 
visualized. The limitations of that study included a small sample size, small delivered fluid volumes, 
and significant motion artefacts from animal movement during the lung studies. Importantly, the 
temporal resolution (1 Hz for nasal studies and 1.33 Hz for lung studies) was too low to accurately 
track the rapid fluid movement. The aim of the present study was to utilise improved image capture 
techniques to permit more accurate monitoring of fluid dosing dynamics in the nose and lungs of 
live mice using two dimensional PCXI. Specifically, we substantially increased the imaging frame 
rate, included larger fluid doses and utilized a paralytic agent during the lung imaging studies to 
minimize unwanted body movements. 
 METHODS 
Experiments were performed on the BL20B2 bending magnet beamline at the SPring-8 
synchrotron radiation facility in Japan. All experiments were approved by the Animal Ethics 
Committee of SPring-8, and of the Women’s and Children’s Health Network (Adelaide). Mice were 
anaesthetized using 80 mg/kg i.p. pentobarbital (Somnopentil, Pitman-Moore, Washington 
Crossing, USA), with an additional 30 mg/kg i.p top-up 10 minutes later, just prior to imaging. Body 
temperature was maintained using an infrared heat lamp and monitored with a rectal thermometer. 
Mice were typically anaesthetized for a maximum of 30 minutes and were humanely killed via 
overdose of pentobarbital after completion of each experiment. 
Imaging setup 
The imaging hutch was located in the SPring-8 Biomedical Imaging Centre, 211 meters from the 
source 14, and the imaging layout was as described previously 9, 13 (see Figure 1). Monochromatic 
18 keV (λ=0.7Å) X-rays were selected using a Si(111) double-crystal monochromator to provide 
both maximum flux and iodine contrast 15. A propagation (sample to detector) distance of 1.35 m 
was chosen to produce optimal phase contrast for airway imaging. X-rays were converted to visible 
light using a GADOX (P43, Gd2O2S:Tb) scintillator coupled to an 85 mm lens (BM5, Hamamatsu 
Photonics) and images were captured using an EMCCD detector (C9100-02, Hamamatsu 
Photonics) and a 200 mm camera lens. The CCD detector had an array size of 1000 x 1000 pixels 
and an 8 µm native pixel size. This setup resulted in an effective isotropic pixel size of 18.8 µm and 
a field of view of 18.8 mm x 18.8 mm. An exposure length of 100 ms was chosen to capture 
sufficient photons to fill the potential dynamic range (214 grey levels) of the detector, provide the 
maximal signal to noise ratio without detector saturation, and minimize blurring from animal 
movement. 
Nasal studies 
Animals were prepared as previously described 13. Briefly, 15 anaesthetized female C57/Bl6 
mice (~20 grams) were individually secured head-high to a polyethylene imaging board 16 with their 
 incisors hooked over a wire loop and their limbs, shoulders and torso taped to the board to 
minimize body movements. The imaging area (head) was brushed with a thin layer of glycerol to 
eliminate air in the fur layer and minimize fur interference in the PCXI images. The imaging board 
was connected to the hutch sample stage such that the mouse was held head-high and the X-ray 
beam passed dorso-ventrally through the nose. A PE10 polyethylene cannula (SteriHealth, 
Melbourne, Australia) was positioned using a micromanipulator so its tip was 1-2mm above the 
right nostril, to simulate our normal (hand-delivered) nasal gene vector delivery setup 1. The 
cannula was connected to a syringe pump (UltraMicroPump III and Micro4 controller, World 
Precision Instruments, Florida, USA), remotely activated from outside the imaging hutch. 
To produce lasting gene expression after a single dose event in our gene transfer studies we 
utilize a 4 µl 0.1 – 1% (typically 0.3%) lysophosphatidylcholine (LPC) airway pre-treatment before 
delivering a 20 µl lentiviral (LV) gene vector dose (typically 107 – 109 tu/ml) to the mouse nose 1, 2, 17, 
18. Our previous study suggested that a 20 µl dose overwhelmed the holding capacity of the mouse 
nose 13, so we sought to test the effect of an intermediate dose volume. For this reason we chose 4 
µl, 10 µl and 20 µl as the surrogate fluid volumes to examine here (n=5 each). A 1:1 mix of the 
strongly X-ray absorbing iodine-based contrast agent iomeprol (Iomeron 350, Bracco-Eisai, Tokyo, 
Japan 19) and water (to produce an isotonic solution) was used as the surrogate fluid for both LPC 
and the LV vector. In three mice we tested the use of saline only as the surrogate fluid to 
demonstrate the effectiveness of using iomeprol for visualizing the fluid location. To ensure 
accurate dose initiation and delivery the syringe and PE tubing were primed and tested prior to 
each experiment. 
Images were captured at 6.67 Hz. After 15 seconds (100 frames) of baseline image collection, 
the contrast mix was delivered in a single bolus at a constant rate of 0.4 µl/sec; thus the 4 µl dose 
was delivered in 10 sec, the 10 µl dose in 25 sec and the 20 µl dose in 50 sec. Mice “sniffed” the 
fluid into one nostril by their normal tidal volume inhalations. The cannula tip did not make contact 
with the mouse nose at any time. Image capture continued for five minutes, creating a dataset 
consisting of a total of 2100 images per mouse. 
 Lung studies 
A similar protocol was used for the lung imaging. Ten mice were anaesthetized, then intubated 
with a 20Ga i.v. catheter (Insyte, Becton Dickinson, Utah, USA) 16. This endotracheal (ET) tube was 
inserted into the trachea to a depth of 22.5 mm from the nose tip, chosen to place the ET tube tip 
below the fifth cartilage ring (approximately half way between the epiglottis and the carina, based 
on measurements made in dissected animals prior to the imaging studies). The catheter Luer hub 
was immediately cut off to enable the ET tube to be directly connected to the ventilator circuit and 
ensure respiratory dead-space was minimized. The imaging area (chest and back) was brushed 
with a thin layer of glycerol to improve image quality. Mice were ventilated at 80 breaths/min with a 
tidal volume of 30 ml/kg (no pressure limit) and ~3 cmH2O of PEEP using a flexiVent small animal 
ventilator (Scireq, Canada). The ventilatory profile was configured with a forced inspiration of 350 
msec and a passive expiration of 400 msec. After connection to the ventilator mice were paralysed 
using pancuronium (Mioblock, 0.5 mg/kg i.p.) to minimize unwanted respiratory and skeletal muscle 
movements. Fluid doses were delivered via a heat-thinned PE10 polyethylene cannula placed 
inside the ET tube via an airtight slit in the silicone ventilator tubing and advanced so that its tip 
extended 5mm below the end of the ET tube 13, 16, a similar depth to that used in our mouse lung 
gene transfer studies 1. The syringe pump was used to remotely deliver the bolus of contrast 
mixture via this smaller cannula. 
Our lung gene transfer studies use doses of 15 to 30 µl 1, so these are the two doses we tested 
(n=5 each). Our previous fluid dosing study suggested that rapid dose deliveries better target the 
conducting airways and minimize dose losses via retrograde movement around the delivery and ET 
tubes 13, so the maximum infusion rate of the syringe pump (~4.2 µl/min) was used for both 
volumes. 
Starting at the beginning of each breath the ventilator triggered acquisition of five images at 
equally spaced intervals of 150 msec. This resulted in three frames during inspiration and two 
frames during the relatively motion-free period after passive-expiration. After 15 seconds of 
 baseline collection (20 breaths, 100 images), a sample of the contrast mix was delivered. For the 
15 µl and 30 µl volumes the fluid was delivered as a single bolus over 3.6 sec and 7.2 sec 
respectively (max infusion rate). Imaging continued for a further 5 minutes creating a dataset 
consisting of a total of 2100 images per mouse. 
Post experimental analyses 
Post processing was performed as previously described 13. All images were flat-field and dark-
field corrected and image subtraction algorithms were used to locate regional changes in image 
brightness (Matlab 2009b, The Mathworks, USA). 
For the nasal studies each frame was subtracted from the best matched baseline image – 
determined by calculating the two-dimensional correlation coefficient between the current frame 
and each of the baseline frames – to locate regions where the image brightness had changed and 
so reveal fluid motion (i.e. background subtraction of the mouse anatomy). A constant threshold of 
128 grey values (1/32 the dynamic range) was used to select only the large intensity changes and a 
3x3 median-filter was applied to reduce noise. The presence and / or motion of the delivered fluid 
was highlighted by pseudo-colouring the original images. The regions where the image became 
darker (more contrast fluid) were coloured with a red to yellow colour scale, and those that became 
lighter were coloured with a blue to purple colour scale (see Figure 2). The volume of contrast fluid 
(i.e. the amount of artificial colour) present in the nose in each image frame was also determined 
semi-quantitatively by summing the pixels in a central vertical region of interest of dimensions 300 x 
1000 pixels from the background subtracted images. This value was calculated for each image 
collected from every mouse and presented as an average over time for each fluid volume. 
The lung studies were processed differently. For these images the brightness difference 
between successive breaths (i.e. frame differencing) was calculated by subtracting each frame from 
the corresponding frame in the previous breath. This technique was used to compensate for the 
greater confounding movements produced by the continuous respiratory and cardiac motion. Each 
frame was converted to an RGB image and the red, green and blue channels were adjusted to 
 show the regions where the brightness decreased (i.e. presence of contrast fluid) in green pseudo-
color. This visualization method minimized the effects of body motion and eliminated the need to 
choose a different threshold for each animal that would complicate between-animal comparisons. 
For high quality motion-detection the background must remain still compared to the foreground 
objects (i.e. the contrast fluid) to be detected, so we made special efforts to minimize the movement 
of the mouse during imaging, hence the use of restraining boards, respiratory-gating and 
respiratory muscle paralysis as described above.  
The amount of contrast fluid that entered the left and right lungs was calculated in a similar 
manner to the nasal study. Each image was divided into left and right halves using a vertical line 
that passed through the carina. The proportion of contrast fluid entering each lung was determined 
by calculating the sum of the pixels in the frame-difference images. Only frames 100 to 250 were 
analysed (i.e. the fluid dosing period) to minimise the contributions of extraneous body movements. 
 RESULTS 
 The small volumes of the 1:1 mixture of water and contrast fluid were well-tolerated by the 
anaesthetized mice. All mice survived to the end of the imaging sequences. Occasional respiratory 
perturbations occurred with the large volume deliveries, but subjectively these appeared to occur at 
a similar incidence to that experienced during our gene transfer studies. 
Nasal dose delivery 
Soon after delivery initiation (see Figure 2; Supplementary Movie 1 shows the full delivery 
sequence) two primary regions of distribution were typically visible; the anterior region (containing 
largely respiratory epithelium) and the more distal and lateral olfactory region. Increasing the 
delivered volume produced progressively greater ‘overflow’ of dose from this portion of the olfactory 
region of the anterior nose into the central nasopharynx. The smallest (4 µl) dose filled one side of 
the anterior nose and then remained essentially unchanged for the duration of the imaging period, 
with no fluid moving into the nasopharynx. At the two higher doses (10 µl and 20 µl) fluid 
‘overflowed’ into the nasopharynx and so could reach more distal airways, the mouth, or the gut. 
This overflow dose subjected the nasopharynx to varying degrees of reciprocating fluid movement 
that periodically re-exposed the nasopharangeal airway tissue to the dosed fluid. 
The dynamics of contrast fluid delivery were tracked by measuring the total image intensity 
change of each frame, compared to baseline, as a surrogate measure of the fluid volume contained 
within the image frame. On average (see Figure 3) there was consistent airway filling in the first 10 
seconds (during which approximately 4 µl of fluid was delivered). For the 4 µl dose there was a 
gradual small reduction after instillation ceased. For the 10 µl dose the amount of contrast fluid 
continued to increase until approximately 14 sec and was followed by a gradual reduction which 
occurred prior to delivery ceasing. At the highest dose (20 µl) the amount of fluid continued to 
increase until approximately 19 sec (at which point approximately 10 µl of fluid had been delivered). 
There was substantial variability in the amount of contrast fluid present thereafter. 
 These studies revealed a number of interesting findings. Firstly, when normal saline was used as 
the dosing agent it could be detected, albeit poorly, and mimicked the gross distribution of the 
contrast agent mix in the upper (anterior and olfactory) nasal airway (data not shown). Regardless 
of the delivered volume, normal saline did not produce sufficient image contrast to consider it a 
useful substitute for the contrast mix in these studies. Secondly, in one mouse that received a 20 µl 
dose of contrast mix the nasopharangeal airflow ceased for ~45 sec along with complete filling of 
the nasopharangeal meatus with contrast fluid (See Supplementary Movie 2) before restarting. 
Thirdly, in many mice exposed to larger doses (10 and 20 µl) ‘overflow’ contrast fluid eventually 
produced irregular periods of reciprocating fluid movement that permitted some fluid to move back 
into the olfactory region (See Supplementary Movie 1). This ‘overflow’ effect also deposited fluid in 
the entrance to the Eustachian tube in the lower nasopharynx. 
 Lung dose delivery 
In this study the progress of delivered fluid into the lung was monitored by the change in X-ray 
contrast between breaths and was represented by green artificial colouring in the airways (see 
Figure 4 and Supplementary Movie 2). The use of a paralytic agent during the lung imaging studies 
minimized unwanted body movements. Both fluid volumes appeared well-tolerated, regardless of 
their effect upon delivery. At the end of the imaging period the ventilatory excursions were normal 
and all animals were alive; heart movements were verified during the post-experimental analyses.  
Movement through bronchi and small airways was heterogeneous when fluid delivery did not 
interfere with lung expansion. Although fluid initially progressed primarily into either the left or right 
mainstem bronchi, in some animals a simultaneous bilateral distribution occurred. In some cases 
fluid moved into the post caval lobe 20, but rarely did it enter the superior lobe 20. Typically the dose 
divided immediately upon entering the upper airways before distributing further into the distal 
airways and alveolar regions. Only in two mice did the bulk of the fluid distribute – over 4 breaths in 
both mice – to the distal airways and periphery in a relatively homogeneous manner. Tracking of 
the pixel sum in the left and right sides of the image showed that there was no statistically 
 significant difference (n.s. paired t-test, n=10) between the amount of fluid entering the left and right 
lungs (see Figure 5). In all but one animal, distribution was equally split between the two sides. 
Together these findings demonstrate that the distribution of fluid doses was not-uniform, both in-
transit or when measured as a final distribution. In some cases the fluid boli did not span the full 
width of the airways, appearing ‘drop-like’ on the airway wall. Nevertheless these partial boli moved 
progressively toward the periphery in concert with ventilatory flows. Depending on the anatomical 
orientation of the particular distal airway region, the fluid movement into that region could appear in 
a “starburst” pattern, clearly revealing the simultaneous distribution into several airway branches at 
once (see Figure 6 and Supplementary Movie 3). It was rare for substantial retrograde movement of 
the fluid dose to occur after it entered the mainstem bronchi. 
In some animals (3 of 10 mice; 1 x 15 µl and 2 x 30 µl) fluid instillation resulted in a respiratory 
pause despite the ventilator continuing to operate, increasing the effective delivery time into the 
lung. In all cases some of the fluid initially expelled from the delivery cannula back-filled between 
the ET tube and the inner tracheal walls and remained trapped there for the duration of the imaging. 
This fluid oscillated in the trachea around the ET tube with oscillations from the ventilator, and 
during respiratory pauses the oscillation was often apparent just distal to the ET tube. The 
oscillating fluid was often not artificially coloured (appearing dark grey) because there was little fluid 
progression between breaths (and thus it was not coloured green by the analysis algorithm). 
Despite the pause, the dose fluid slowly progressed down the trachea and normal ventilation 
appeared to resume when the oscillating fluid front reached the carina. Figure 7 shows the 
ventilator airway pressure spanning one of these events; airway pressure increased substantially 
and was sustained at a higher level during the pause, reducing immediately to slightly above the 
baseline pressure when normal ventilation resumed. In all animals a peak in airway pressure 
observed at delivery of the dose was followed by a gradual reduction throughout the remainder of 
the study. 
 DISCUSSION 
The primary goal of this study was to document and understand the dynamics of fluid bolus dose 
delivery into the nose and trachea of live mice using synchrotron PCXI in a manner that would 
improve understanding of airway gene transfer dosing in mice. To our knowledge these studies 
represent the first detailed analysis of real-time fluid dose delivery and distribution effects in the 
airways of intact mice, and we suggest these findings have wider application to the understanding 
of the variability and destinations of fluid doses delivered into mouse airways for many other types 
of respiratory research. 
Our previous fluid dosing study 13 was limited by the slow image capture rate. In the nose the 
capture rate was insufficient for visualizing the rapid fluid movements – for example the filling of the 
nose (See Supplementary Movie 1) – that occurred upon dosing. In the lung the effectiveness of 
ventilation could not be visualized because only a single image was taken immediately prior to each 
ventilator-driven inspiration (i.e. at the end of each breath). The primary effect was that in the lung 
the delivery dynamics within each breath, and their implications on dose distribution, could not be 
appreciated. In particular, the cessation of breathing that occurred in this current study in some 
mice immediately after fluid delivery may have also occurred in the previous study, but could not 
have been detected with that slower capture rate. In addition, the precision with which fluid 
movement could be tracked was improved in this study through the use of a paralytic agent; this 
minimized the occurrence of confounding respiratory and skeletal muscle movements. 
Nasal airways 
Our findings provide information pertinent to mice oriented vertically for nasal fluid dose delivery, 
as is common in a range of research settings. We have shown that specific regions of the nasal 
airways can be targeted by altering the dose volume. Furthermore, it is unlikely that the lung will be 
dosed if volumes less than ~ 4 µl (in ~ 20 g mice) are used. These dosing differences will be of 
value in targeting only the olfactory region for drug treatment studies. While the use of larger 
volumes will access the nasopharyngeal airway, it is difficult to predict whether fluid movement 
 would be localized to the wall on the treated side (Figure 2c), or reach all of the nasopharynx via 
the reciprocating movement of the dose that often eventuates (e.g. as occurred after the frame 
shown in Figure 2c; see Supplementary movie 1). The presence of reciprocating dose fluid after 
larger volumes also increases the likelihood of retrograde fluid delivery into the contralateral 
anterior nasal airways, and this effect may prevent use of the un-dosed nasal airway as a within-
animal control site. Alternatively, the reciprocating fluid will tend to coat the circumference of the 
nasal lumen which may be of benefit in circumstances where treatment of the entire nasopharynx 
lumen is desired. 
As the contrast fluid entered the nasal airway the magnitude of the difference in pixel intensity 
from baseline increased in proportion to the amount of contrast agent present. Figure 3 showed that 
we could provide a degree of quantification of the dynamic movement of the fluid through the nasal 
airways. That analysis revealed the ‘holding capacity’ of the portion of the mouse nose shown in 
these images is between 4 and 10 µl (~7.5 µl based on Figure 3). The implication for our nasal 
airway gene transfer studies is that 4 µl pre-treatment doses will be limited to the anterior nose, 
while 20 µl gene vector doses will reach both the nose and more distal regions such as the lung or 
gut, as proposed in our previous study 13. 
Lung airways 
Despite using identical dose delivery conditions for each mouse there was large variability in the 
manner in which the fluid distributed through the airways, as well as its ultimate destination in the 
lung. For most deliveries the fluid initially went to either the left or right bronchi, although in some 
(n=2) a simultaneous bilateral delivery occurred. In all cases the ET tube was set to a standard 
depth, well above the carina, however, the placement of the tip (i.e. orientation and angle) may 
have influenced this outcome. The preferential dosing of one side of the lung could be an effect of 
the ventilator and ET tube, or alternatively, it could be a normal physiological response to fluid 
dosing that has not previously been visualised. Importantly, this finding suggests that expectations 
of uniform dosing cannot be predicted from a bolus delivery into the upper trachea. Despite the 
 observed variability in dosing there was no statistically significant difference between the proportion 
of fluid measured entering the left and right lungs. This finding agrees with previously published 
data 21. The presence of ‘drop-like’ as well as full-lumen fluid advancement down the bronchi further 
reveals the variability that is present after otherwise uniform dosing procedures are performed. 
These findings help explain the patchiness of lung gene transfer we have experienced 1, both within 
and between animals. 
This technique also has the ability to highlight structural features within the lung. For example, 
the airway trifurcations that are a characteristic of the branching in mouse lung were revealed 
dynamically as the fluid doses split to the daughter airways (Figure 6 and Supplementary Movie 3). 
In all animals some fluid was trapped behind and around the projection of the ET tube in the 
trachea, with the distal edge of the fluid oscillating with ventilation. The presence of the ET tube and 
the viscosity of the dosing fluid may have influenced the retention or progression of fluid into the 
lung, presumably via surface tension effects. We speculate that the splitting of the fluid front by the 
carina permitted the trapped fluid to be dispersed into the mainstem bronchi allowing normal lung 
movement to resume. The return of airway pressure to near baseline (Figure 7) could serve as an 
indicator of movement of a trapped tracheal dose into the main bronchi to distribute into the distal 
lung. The gradual reduction in airway pressure noted in all animals after fluid dosing is consistent 
with gradual dispersion and absorption of the delivered dose observed in the image sequences. 
Compared to PET, SPECT or planar gamma camera imaging, the spatial and temporal 
resolution of this PCXI technique are far superior, and these results could not have been obtained 
using any other technique. The high flux produced by the synchrotron (allowing high temporal 
resolution), combined with the ability to perform phase contrast imaging (resulting in excellent 
anatomical detail and fluid localisation) makes this technique unique in its ability to capture dynamic 
images of fluid dosing. We believe that this research tool has the ability to answer many questions 
related to fluid dosing, pulmonary drug delivery and hopefully in the future to aerosol delivery to the 
airways of various animal models. However, in its current form and at the resolution used it is 
 unlikely to have application in humans, primarily due to the radiation level present (the amount of 
radiation delivered increases to the 4th power of the resolution 22). Nevertheless, some synchrotron 
facilities have begun to implement human clinical programs for other types of analyses including 
mammographic imaging 23 and synchrotron stereotactic radiation therapy for cancer treatment 24. 
The use of high-energy monochromatic synchrotron X-rays also enables phase effects to be 
detected without any absorption using a technique such as diffraction enhanced imaging 25. This 
means it is theoretically possible to obtain X-ray phase images with zero absorbed dose. Clinical X-
ray systems that utilise this mechanism are currently under development. With continuing advances 
in technology human applications of synchrotron radiation are expected to evolve towards 
advanced, dose-acceptable imaging for use in the clinic. 
This study has several limitations. The primary limitation is the requirement of using a 
synchrotron – of which there are approximately 40 worldwide – to gather these image sequences 
with high temporal and spatial resolution. The need to deliver ionising radiation also affects the type 
of studies that can be performed; low delivered radiation doses are essential if animals are allowed 
to recover after an imaging experiment. Nonetheless, we propose that these findings are unique 
and especially informative for respiratory researchers using mouse models. The requirement for a 
synchrotron also makes it logistically very difficult to perform this type of study using a reporter 
gene vector fluid dose (rather than a surrogate contrast fluid dose) which would allow the dose 
distribution to be correlated with resulting gene expression. The Biosafety level 2 conditions 
required for delivering our HIV-1 based lentiviral vector are difficult or impossible to achieve in a 
synchrotron imaging hutch.  
The iodine-based contrast agent is not a normal dose agent for airways and may alter the 
physiological response; however, we demonstrated that saline alone cannot be detected with 
sufficient sensitivity to be of value in monitoring dose distributions after delivery. In this study we did 
not perform a detailed calibration to determine the relationship between X-ray absorption and the 
amount of contrast agent present in the airways. As a result we cannot precisely quantify the 
amount of fluid present in the airways. However, in future studies such calibrations should enable 
 accurate fluid volume quantification to be performed. Though more important for long term studies, 
the presence of the ET tube in the trachea after dosing is different to normal practice (it is typically 
removed after dosing) but was necessary to maintain ventilation in these paralysed animals. The 
use of a paralytic meant that the mice could not cough or take large breaths when their airways 
were filled with dose fluid, so this may have altered the manner in which fluid distributed. The 
upright posture may also alter the fluid distribution; however this is the same technique we use for 
our actual gene vector deliveries into the nose and lung. Finally, in the lung analyses where there is 
little change in fluid position between matching time-points in sequential breaths the fluid movement 
within a breath is not well highlighted, resulting in the oscillation of fluid around the ET tube not 
being well visualized. Conversely, small lung-edge movements during breaths, particularly adjacent 
to the heart, results in those edges being coloured green even though they do not originate from 
fluid movements. Despite these limitations the movement of the green-coloured airway fluids 
remains easy to visualize. 
In summary, we have shown the value of high acquisition rate PCXI in discovering the nature of 
fluid flow into the mouse respiratory system. Our findings suggest that assumptions of even 
distributions in the nose or lung are unfounded; analyses should be mindful of the lack of 
distribution uniformity of agents delivered in fluid form. 
SUPPLEMENTARY FILES 
The supplementary files contain movie sequences showing the fluid motion in the mouse nose 
and lung, and are the source of the images shown in the Figures. Images were captured at 6.67 Hz 
and include 3 seconds of baseline before fluid delivery. All videos are Quicktime MP4 files, were 
encoded using the H.264 codec and can be played using the free VLC Media Player (available at 
http://www.videolan.org/vlc/). 
Supplementary Video 1 | Nasal dose-response to instilled contrast fluid 
Typical responses to 4 µl (left), 10 µl (centre) and 20 µl (right) fluid (1:1 iomeprol and water mixture) 
doses to the nose of three different mice. The retention of fluid in the upper portion of the nose and 
 the overflow of additional fluid into the nasopharynx is apparent. Doses were delivered at the same 
rate and last for 10, 25 and 50 sec respectively. The pseudo-colouring of each frame image results 
was produced by a background subtraction algorithm referenced to the first (pre-delivery) image. 
Compared to the reference frame, the red/yellow shows areas with increased contrast present, and 
the purple/blue colour being regions where contrast has been lost. Some movement of the mice is 
visible over time, as shown by the purple/blue coloured areas of movement of the hair, skin, head 
and jaws. 
Supplementary Video 2 | Lung dose-response to instilled contrast fluid 
Green highlighting shows the typical responses to 15 µl (left) and 30 µl (right) of contrast fluid 
dosed into the lungs of two different mice. Fluid was delivered as a single bolus over 3.6 sec and 
7.2 sec respectively (max infusion rate). The indicator in the top right corner of each image shows 
the temporal position of the captured frame. When fluid is first expelled it moves retrograde along 
the cannula and the ET tube (during expiration) and then enters the trachea and conducting 
airways (during inspiration). In the mouse on the right (30 µl) fluid is retained in the trachea for ~20 
breaths and resulted in a temporary halt in lung inflating despite ventilation continuing. 
Subsequently, fluid is then expelled into the conducting airways and inflation begins again. 
Supplementary Video 3 | Fluid bolus splitting at an airway trifurcation 
Green highlighting shows the progression of a 15 µl fluid dose into the lungs of one mice. Fluid was 
delivered as a single bolus over 3.6 (max infusion rate). In this mouse a fluid bolus is visible moving 
down the left main bronchus before splitting into three separate boli at an airway trifurcation. 
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 FIGURE CAPTIONS 
Figure 1 | Synchrotron imaging setup 
The in vivo airway synchrotron phase contrast X-ray imaging setup. Mice are held vertically on an 
x-y-rotation stage in the imaging hutch, 211 m from the X-ray source. A propagation (sample to 
detector) distance of 135 cm was used. 
Figure 2 | Nasal bolus dose delivery 
Representative images from three separate mice showing the dose distribution after delivery of fluid 
boluses into the nose. From L to R the doses are 4 µl, 10 µl and 20 µl. These frames were captured 
~17 seconds after the initiation of each fluid delivery. The dotted region contains a mixture of 
respiratory and transitional ciliated epithelium. 
Figure 3 | Average pixel intensity over time for each group 
Vertical blue, red and green dashed lines mark the end of the 4 µl, 10 µl and 20 µl dose deliveries, 
respectively. Note that the initial constant increase represents filling of the anterior nose. The 
change in the slope of the lines (10 µl at 14 sec and 20 µl at 19 sec) reflects the fluid overflowing 
from the posterior nasopharynx and disappearing from the field of view (likely into the trachea). 
Note that the green, red and blue plots are averages for each mouse in the 4 µl, 10 µl and 20 µl 1:1 
contrast mix groups respectively, but the purple line is the average of the 4 µl, 10 µl and 20 µl saline 
mice since there was no difference between these groups. 
Figure 4 | Lung bolus dose delivery 
Images from two separate mice showing the delivery of fluid boluses into the lungs via a cannula 
within the endotracheal tube. The left image shows a 15 µl delivery and the right a 30 µl delivery. 
Note that both images are taken in the passive expiratory phase, shown by the indicator in the top 
right corner of each image. These frames were captured 25 frames (i.e. five breaths) after the 
initiation of dosing. The movement of the fluid through the conducting airways towards the alveoli is 
 clearly visible in both animals. This panel is taken from Supplementary Movie 2 and although not 
visible here, fluid movement is detectable for longer in the 30 µl delivery than the 15 µl delivery. 
Figure 5 | Proportion of fluid delivered to each lung 
The mouse lung anatomy was simplified and assumed to consist of only left and right lung lobes 
that were divided along a vertical line passing through the carina. The amount of fluid entering each 
lung was semi-quantatively calculated based on the sum of the pixels from the frame-difference 
images, and was not statistically significantly different (n.s. paired t-test, n=10). Only in one mouse did 
substantially more fluid enter the left lung than the right.  
Figure 6 | Fluid bolus splitting at an airway trifurcation 
Four images from one mouse show a fluid bolus splitting into three separate boli at an airway 
trifurcation. Each image is ~6.5 x 6.5 mm2 and is located approximately in the middle of the left 
lung. Images are spaced 300 msec apart, and start ~10 breaths (50 frames) after a 15 µl dose was 
delivered. This panel is taken from Supplementary Movie 3. 
Figure 7 | Airway pressure during lung dose delivery 
The change in airway pressure during fluid delivery is measured by the ventilator pressure 
transducer. In this case respiration paused immediately after fluid delivery despite ventilation 
continuing, with normal respiration returning approximately 40 seconds later. 
